ATAZANAVIR CIPLA atazanavir 150 mg capsule blister pack

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

atazanavir sulfate, Quantity: 170.85 mg (Equivalent: atazanavir, Qty 150 mg)

Disponível em:

Cipla Australia Pty Ltd

DCI (Denominação Comum Internacional):

Atazanavir sulfate

Forma farmacêutica:

Capsule, hard

Composição:

Excipient Ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; Gelatin; sodium lauryl sulfate

Via de administração:

Oral

Unidades em pacote:

6 capsules

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

Atazanavir is indicated for the treatment of HIV 1 infection, in combination with other antiretroviral agents. This indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts from controlled studies (See Clinical Trials).

Resumo do produto:

Visual Identification: White to pale yellow granules filled in size 1 hard gelatin capsule with maroon cap & white body spin printed with Cipla 150 on cap with white ink.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 15 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Status de autorização:

Licence status A

Data de autorização:

2017-08-30